https://www.selleckchem.com/products/mk-8617.html
285, stage II or III; P=.077). Multicenter external validation did not show a better OS in the adjuvant therapy group (P=.531). On multivariable analysis, only perineural invasion (PNI) was identified as an adverse prognostic factor in resected inv-IPMN (HR 4.844; 95% CI 1.696-13.838, P=.003). inv-IPMN has a more indolent course than PDAC. Current strategy of adjuvant therapy may not improve the OS in patients with resected inv-IPMN. Further investigations on the potential role of adjuvant therapy in inv-IPMN are mandatory. inv-IPMN has
Like
Comment
Share
